07:45:43 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

2024-10-31 Kvartalsrapport 2024-Q3
2024-07-11 Kvartalsrapport 2024-Q2
2024-06-12 Ordinarie utdelning QLINEA 0.00 SEK
2024-06-11 Årsstämma 2024
2024-05-03 Kvartalsrapport 2024-Q1
2024-02-27 Bokslutskommuniké 2023
2023-11-02 Kvartalsrapport 2023-Q3
2023-07-13 Kvartalsrapport 2023-Q2
2023-07-03 Extra Bolagsstämma 2023
2023-06-13 Årsstämma 2023
2023-05-24 Ordinarie utdelning QLINEA 0.00 SEK
2023-05-04 Kvartalsrapport 2023-Q1
2023-02-16 Bokslutskommuniké 2022
2022-11-03 Kvartalsrapport 2022-Q3
2022-07-14 Kvartalsrapport 2022-Q2
2022-05-25 Ordinarie utdelning QLINEA 0.00 SEK
2022-05-24 Årsstämma 2022
2022-05-05 Kvartalsrapport 2022-Q1
2022-02-17 Bokslutskommuniké 2021
2021-11-04 Kvartalsrapport 2021-Q3
2021-07-15 Kvartalsrapport 2021-Q2
2021-05-26 Ordinarie utdelning QLINEA 0.00 SEK
2021-05-25 Årsstämma 2021
2021-05-06 Kvartalsrapport 2021-Q1
2021-02-18 Bokslutskommuniké 2020
2020-11-05 Kvartalsrapport 2020-Q3
2020-07-16 Kvartalsrapport 2020-Q2
2020-05-27 Ordinarie utdelning QLINEA 0.00 SEK
2020-05-26 Årsstämma 2020
2020-05-07 Kvartalsrapport 2020-Q1
2020-02-13 Bokslutskommuniké 2019
2019-11-07 Kvartalsrapport 2019-Q3
2019-07-18 Kvartalsrapport 2019-Q2
2019-05-23 Ordinarie utdelning QLINEA 0.00 SEK
2019-05-22 Årsstämma 2019
2019-05-03 Kvartalsrapport 2019-Q1
2019-02-14 Bokslutskommuniké 2018

Beskrivning

LandSverige
ListaSmall Cap Stockholm
SektorHälsovård
IndustriMedicinteknik
Q-Linea är verksamt inom medicinteknik. Bolaget är specialiserat inom forskning och utveckling av instrument och förbrukningsartiklar. Produkterna används huvudsakligen vid behandling av infektionssjukdomar och blodförgiftning, och innefattar diagnostik- och analysverktyg, samt övrig grundläggande provhantering. Tekniken baseras på den så kallade ID- samt AST tekniken. Bolaget grundades 2008 och har huvudkontoret i Uppsala.
2022-04-21 13:00:00

Q-linea AB (publ) (OMX: QLINEA) - Q-linea today announces that it will host an exhibit at the most important trade fair, European Congress of Clinical Microbiology & Infectious Diseases (ECCMID), which this year will be held in Lisbon 23-26 April 2022. Q-linea will present ASTar®, including the new concept to include smooth, comprehensive, and fast analysis of isolates. Q-linea will also present the Podler® concept, the first portable blood culturing device, capable of utilising transportation time and expediting results.

ASTar is commercially available in Europe for fully automated analysis of positive blood cultures, but the platform is built to expand into other tests. At ECCMID, the automated loading station for isolate analysis will be presented as a future extension of the capabilities of ASTar. This will allow the rapid analysis of isolates using only the AST disc as a consumable.

Q-linea will also present Podler, including the portable Podler unit as well as the Podler Station that acts as a hub in the laboratory. Podler enables immediate incubation, agitation, and continuous monitoring following blood draw. Thereby making every hour count and reducing the time taken for blood culture analysis.

"I am excited to present so many products in development and how they seamlessly integrate with both ASTar and other laboratory workflows. We plan for ASTar to be extended, to also analyze isolates. Since only the AST disc is used, the product can be offered at a lower price compared to our fully automated analysis for positive blood cultures. It is thrilling to present a radical new way of looking into blood culturing with Podler. It has the potential to enable a shorter time to result for all patients with sepsis, no matter the distance between laboratory and hospital. This is another step on the path toward equitable healthcare. The products we showcase will all be a part of our goal at Q-linea to contribute to future-proof healthcare, by providing transformative solutions for infectious disease diagnostic. We will exhibit in booth 1-6”, said Jonas Jarvius, CEO of Q-linea.

ASTar Instrument and ASTar BC G- Kit are CE-marked but not FDA 510(k)-cleared and not available for sale in the United States. Podler is not currently commercially available.